AustraliaHealth

Imricor Medical Systems (ASX:IMR) announced that the US Food and Drug Administration has granted 510(k) clearance for its Vision-MR Diagnostic Catheter.

Nova Eye Medical (ASX:EYE) has reported a record sales performance for the December 2025 quarter, with global revenue reaching US$6.1 million.

CLINUVEL Pharmaceuticals (ASX:CUV) has begun dosing in a preclinical study of its controlled-release injectable peptide platform, VLRX-L.

Radiopharm Theranostics (ASX:RAD) has increased its ownership stake in Radiopharm Ventures, a joint venture with The University of Texas MD Anderson Cancer Center, from 75% to 87.5%.

Vitura Health (ASX:VIT) has appointed finance executive Andrew Cook as its CFO. Based in Queensland, Cook is expected to assume the role in the third quarter of FY26.

Mesoblast (ASX:MSB), a global leader in allogeneic cellular therapies for inflammatory diseases, reported a 60% increase in Ryoncil (remestemcel-L-rknd) sales, generating US$35.1 million in gross revenue for the December 2025 quarter.

Hydrix (ASX:HYD) has announced that its wholly owned subsidiary, Hydrix Services, has entered a contract with SynCardia Systems, a subsidiary of Picard Medical, to commence the initial development phase of SynCardia's next-generation fully implantable total artificial heart, known as the Emperor.

Alcidion Group (ASX:ALC) has been selected as the preferred supplier for University Hospitals Sussex NHS Foundation Trust's new electronic patient record system.

Syntara (ASX:SNT), a clinical-stage drug development company, has announced the completion of patient recruitment for its Phase 2, randomised, double-blind, placebo-controlled trial of SNT-4728.

Nyrada (ASX:NYR), a clinical-stage biotechnology company developing TRPC ion channel inhibitors, has received approval from the Human Research Ethics Committee to commence its Phase 2a clinical trial of Xolatryp

Australian-Singaporean regenerative medicine company Osteopore (ASX: OSX) has secured an exclusive licensing agreement with Accelerate for a pioneering Heparan Sulphate bioactive technology platform.

LTR Pharma (ASX:LTP) announced that its Phase 1 clinical study of SPONTAN nasal spray has been accepted for podium presentation at the World Meeting on Sexual Medicine 2026.